Genelux (GNLX)
Develops Olvi-Vec, an oncolytic virus therapy for platinum-resistant ovarian cancer.
$2.52
vs last close−0.09 (−3.45%)
In millions of USD, except per-share figures
| In millions | Q3 FY23Sep 2023 | Q4 FY23Dec 2023 | Q1 FY24Mar 2024 | Q2 FY24Jun 2024 | Q3 FY24Sep 2024 | Q4 FY24Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross profit | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 5 | 7 | 8 | 7 | 7 | 10 | 8 | 8 | 8 | 9 | 8 | 10 | |
| Research & development | 3 | 4 | 4 | 4 | 4 | 7 | 5 | 5 | 5 | 6 | 5 | 7 |
| 2 | 3 | 4 | 2 | 3 | 3 | 3 | 3 | 3 | 4 | 3 | 3 | |
| Selling & marketing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| General & administrative | 2 | 3 | 4 | 2 | 3 | 3 | 3 | 3 | 3 | 4 | 3 | 3 |
| Other expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating income | −5 | −7 | −8 | −7 | −7 | −10 | −8 | −8 | −8 | −9 | −8 | −10 |
| 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | |
| Interest income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Interest expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other non-operating income | 0 | 0 | 0 | 0 | 0 | −1 | 0 | 0 | 0 | 1 | −1 | 0 |
| Income before tax | −5 | −7 | −8 | −7 | −6 | −9 | −7 | −7 | −8 | −9 | −7 | −9 |
| Net income from continuing operations | −5 | −7 | −8 | −7 | −6 | −9 | −7 | −7 | −8 | −9 | −7 | −9 |
| Net income | −5 | −7 | −8 | −7 | −6 | −9 | −7 | −7 | −8 | −9 | −7 | −9 |
| EPS, basic | −$0.20 | −$0.25 | −$0.29 | −$0.22 | −$0.19 | −$0.27 | −$0.21 | −$0.20 | −$0.21 | −$0.25 | −$0.22 | −$0.21 |
| EPS, diluted | −$0.20 | −$0.25 | −$0.29 | −$0.22 | −$0.19 | −$0.27 | −$0.21 | −$0.20 | −$0.21 | −$0.25 | −$0.22 | −$0.21 |
| Weighted average shares, basic | 27 | 27 | 27 | 30 | 35 | 31 | 35 | 38 | 38 | 37 | 33 | 45 |
| Weighted average shares, diluted | 27 | 27 | 27 | 30 | 35 | 31 | 35 | 38 | 38 | 37 | 33 | 45 |
| EBITDA | −5 | −7 | −8 | −6 | −6 | −9 | −7 | −7 | −8 | −10 | −7 | −9 |
| Depreciation & amortization | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBIT | −5 | −7 | −8 | −7 | −6 | −9 | −7 | −7 | −8 | −10 | −7 | −9 |